Abstract

The Duluth Clinic has worked for the past thirteen years to develop a multi-disciplinary organization involved in the care of oncology patients and to function as a clinical cancer research unit for the geographic area. We have been joined by the Thunder Bay Regional Cancer Centre in Thunder Bay, Ontario which has a large geographic area also. The Duluth Clinic was a founding member of the North Central Cancer Treatment Group in 1978 and has functioned as a CCOP organization for the past five years. During this time, the Duluth CCOP has actively entered patients onto clinical group protocols (762 cancer control patients, 1,765 cancer treatment patients), has assisted in the development of new programs, functioned as study chairs on numerous protocols, and has presented frequently at national meetings. All of the disciplines in oncology are brought together under the direction of this CCOP. An excellent working relationship is established with the NCCTG, and data of unexcelled quality is generated, as shown by our past performance. Geographically, the Duluth CCOP is the only source providing the benefits of clinical cancer research to this large geographic area. The plan is to continue to bring the advantages of clinical research to patients, to bring new programs (such as through the National Surgical Adjuvant Breast Program) to the area, and to continue to increase efforts in cancer prevention, cancer control, and oncology rehabilitation. The North Central Cancer Treatment Group functions as the primary research base with the secondary research bases being the Eastern Cooperative Oncology Group, the Children's Cancer Study Group, and the National Surgical Adjuvant Breast Program. The goal of the Duluth CCOP is to accrue over 200 patients per year onto cancer treatment protocols and 400 patients onto cancer control programs. By virtue of the already established programs and the commitment to quality, it is believed that a high level of productivity and quality can be maintained.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035269-11
Application #
2088906
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1983-09-01
Project End
1995-05-31
Budget Start
1994-06-01
Budget End
1995-05-31
Support Year
11
Fiscal Year
1994
Total Cost
Indirect Cost

  Institution

Name
Duluth Clinic, Ltd.
Department
Type
DUNS #
City
Duluth
State
MN
Country
United States
Zip Code
55805

  Publications

Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Navari, Rudolph M; Qin, Rui; Ruddy, Kathryn J et al. (2016) Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med 375:134-42
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43
Dueck, A C; Singh, J; Atherton, P et al. (2015) Endpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance). Osteoporos Int 26:1971-7
Leal, Alexis D; Qin, Rui; Atherton, Pamela J et al. (2014) North Central Cancer Treatment Group/Alliance trial N08CA-the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890-7
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Loprinzi, Charles L; Qin, Rui; Dakhil, Shaker R et al. (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997-1005

Showing the most recent 10 out of 172 publications